Translational gastroenterology and hepatology
Cure8 research brief
Why This Matters
For people hospitalized with acute severe UC, the findings suggest that measuring early infliximab pharmacokinetics could help personalize rescue therapy and potentially reduce colectomy risk by identifying who may need intensified dosing versus who may not benefit.
Who Should Pay Attention
Adults with acute severe ulcerative colitis, clinicians managing inpatient ASUC and IBD specialists, researchers studying biologic pharmacokinetics and personalized dosing, and patients on infliximab or considering rescue therapy.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthFull source text
What To Know
This editorial summarizes the PREDICT-UC randomized trial and linked pharmacokinetic analyses exploring different infliximab induction schedules for corticosteroid-refractory acute severe ulcerative colitis (ASUC).
The trial compared standard, accelerated, and intensified IFX induction regimens and—on primary endpoints—did not find an overall superiority for an initial 10 mg/kg dose versus 5 mg/kg by day 7.
PK analyses highlighted that early IFX clearance (day 1–7) predicted short-term response and that high faecal loss of IFX correlated with inflammation and poorer outcomes.
The piece emphasizes that total IFX exposure over 90 days was similar across trial arms, which may explain the lack of clinical differences, and suggests that individualized strategies guided by early PK (clearance and faecal loss) could identify patients who might benefit from intensified dosing.
It notes limitations in the trial dosing schedules compared with some real-world intensified regimens that front-load larger cumulative doses.
Practical takeaway: early measurement of IFX pharmacokinetics (including drug levels and markers of faecal loss/inflammation) may help distinguish patients likely to benefit from dose intensification versus those needing alternative therapy; this is presented as an avenue for personalized rescue therapy rather than a definitive treatment change.
Keep In Mind
This article is an editorial summarizing the PREDICT-UC trial and linked prospective PK study; it does not present new randomized trial data beyond the cited studies. PREDICT-UC used specific induction schedules and total 90-day exposures that may differ from some real-world intensified regimens; results may not generalize to all dosing strategies.
The PK findings are hypothesis-generating for personalized dosing and would influence practice only alongside clinical judgment and guideline updates.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationTranslational gastroenterology and hepatology
AuthorsPovlsen S, Hall R, Owen H +2 more
Study typeEditorial
Indexed viaEurope PMC
Source typeResearch paper
PublishedJan 1, 2026, 12:00 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
Upadacitinib for Acute Severe Ulcerative Colitis: Real-World Tertiary Care Outcomes.
Hospitalized patients with acute severe ulcerative colitis often need rescue therapy to avoid colectomy.
Intestinal ultrasound: a non-invasive alternative to monitor and predict biologic treatment persistence in patients with inflammatory bowel disease.
A non-invasive test (intestinal ultrasound) that predicts whether patients stay on biologic therapy could reduce the need for frequent endoscopy and help guide monitoring decisions.